Feb 14 (Reuters) - British drugmaker AstraZeneca Plc reported an 8 percent rise in product sales for the fourth quarter on Thursday, beating analysts’ expectations on the back of strong demand for newer drugs including cancer medicines.
Product sales in the three months ended Dec. 31 rose to $5.77 billion at constant currency, helping return the company to annual sales growth for the first time since 2014.
Analysts had forecast product sales of $5.66 billion, according to a company provided consensus.
The company also said that it had made extensive preparations for Brexit and assumed that Britain’s departure from the European Union would be “orderly” even if it leaves without a deal with Brussels. (Reporting by Pushkala Aripaka and Ankur Banerjee in Bengaluru; editing by Patrick Graham)